[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Shanghai East Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":604},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,34,0,25,[9,41,69,93,119,147,169,199,222,247,272,296,316,336,360,381,406,433,455,476,499,521,541,559,579],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100645184","a-preliminary-clinical-study-protocol-for-evaluating-the-efficacy-and-safety-of-pulse-electric-field-ablation-systems-in-treating-adult-type-2-diabetes-mellitus-with-suboptimal-drug-control-100645184",false,"NCT07678866","A Preliminary Clinical Study Protocol for Evaluating the Efficacy and Safety of Pulse Electric Field Ablation Systems in Treating Adult Type 2 Diabetes Mellitus With Suboptimal Drug Control","Inclusion Criteria:\n\n1. Ages 18-70.\n2. At least 6 months prior to enrollment, the patient must have been diagnosed with type 2 diabetes mellitus.\n3. The glycated hemoglobin level is 7.5%-10.5%.\n4. BMI 2 7-40 kg\u002Fm2.\n5. Patients who, within 12 weeks prior to screening, were treated with 2-3 oral hypoglycemic agents yet still had poorly controlled blood glucose levels, and could maintain the same medication regimen throughout the trial; or those whose blood glucose control was suboptimal despite lifestyle modifications.\n6. Stable body weight (defined as a weight change of \\\u003C5% within 5 weeks prior to screening)\n7. Donation of blood is prohibited during the trial participation period.\n8. The subject must sign an Informed Consent Form (ICF), demonstrating their understanding of the purpose and procedures required for this study and their willingness to participate.\n9. Be willing and able to comply with all requirements specified in the trial, including but not limited to completing the required assessments, adhering to the visit schedule, and complying with lifestyle restrictions.\n10. Fertile female subjects must have a negative urine pregnancy test result during screening and must use contraception throughout the study period.\n\nExclusion Criteria:\n\n1. Diagnosed with type 1 diabetes mellitus.\n2. Severe diabetes-related complications such as diabetic ketoacidosis or hyperosmolar non-ketotic coma.\n3. Fasting serum C-peptide \\\u003C1 ng\u002FmL (333 pmol\u002FL).\n4. Over the past two years, insulin of any type has been used for more than 1 month (excluding treatment for gestational diabetes mellitus).\n5. History of ≥1 severe hypoglycemic episode within the past 6 months (defined as requiring assistance from a third party).\n6. Currently using a GLP-1RA or a dual GLP-6\u002FGIP agonist.\n7. Known autoimmune diseases.\n8. Previous gastrointestinal surgery that has altered the anatomical structure of the digestive tract or may limit duodenal resection, such as Billroth II, Roux-en-Y gastric bypass, gastric banding, or other similar procedures\u002Fdiseases.\n9. A known history of upper gastrointestinal structural or functional disorders may impede device passage through the upper gastrointestinal tract or increase the risk of tissue injury during endoscopic procedures, including upper gastrointestinal strictures, esophageal-gastric varices, large diverticula, or other severe esophageal, gastric, or duodenal pathologies.\n10. History of gastroparesis.\n11. Acute gastrointestinal disease has occurred within the past 7 days.\n12. A history of irritable bowel syndrome, radiation enteritis, or other inflammatory bowel diseases such as Crohns disease and celiac disease is known.\n13. Previous history of chronic or acute pancreatitis.\n14. Active hepatitis or active liver disease, or an alanine aminotransferase (ALT) level\\>3.0 times the upper limit of normal (ULN) as determined by the central laboratory during screening evaluation.\n15. Currently, vitamin K antagonists such as warfarin are being used, or oral anticoagulants (DOCA) that cannot be safely discontinued are being administered.\n16. Patients currently using P2Y12 inhibitors (clopidogrel, prasugrel, ticagrelor) that cannot be discontinued within 7 days prior to surgery.\n17. Nonsteroidal anti-inflammatory drugs (NSAIDs) must not be discontinued within 4 weeks after treatment. Alternative use of acetaminophen and low-dose aspirin is permitted.\n18. Systemic glucocorticoids (excluding topical, ocular, or inhaled formulations) were administered continuously for more than 12 days within 10 weeks prior to screening.\n19. Use medications known to affect gastrointestinal motility\n20. Individuals currently using weight-loss medications or over-the-counter weight-loss drugs.\n21. Participate in any structured weight loss program or endoscopic weight loss intervention within 6 months after screening.\n22. Persistent anemia, defined as hemoglobin \\\u003C10 g\u002FdL.\n23. Known hemoglobinopathies, hemolytic anemia or sickle cell anemia, or other known hemoglobin abnormalities that may interfere with HbA1c measurement.\n24. A history of blood donation or transfusion within 3 months prior to screening.\n25. Unstable or paroxysmal arrhythmia.\n26. Any of the following cardiovascular diseases occurred within 6 months prior to screening: acute myocardial infarction (AMI), cerebrovascular accident (stroke), or hospitalization due to congestive heart failure.\n27. History of valvular heart disease or chronic heart failure (NYHA class III or IV).\n28. Individuals with known immunocompromised status, including but not limited to those who have undergone organ transplantation, chemotherapy, or radiotherapy within the past 12 months, those with clinically significant leukopenia, those who are positive for human immunodeficiency virus (HIV), or whose immune status makes them unsuitable for clinical trial participation as determined by the investigators.\n29. There is secondary hypothyroidism or poorly controlled primary hypothyroidism (TSH levels exceed the normal range during screening).\n30. During the examination, do not implant any electronic devices that cannot be turned off (such as implantable cardiac pacemakers).\n31. A duodenal or biliary stent is in place.\n32. Patients with contraindications to upper gastrointestinal endoscopy or intravenous anesthesia.\n33. Currently diagnosed with malignant tumor or with a history of malignant tumor within the preceding 5 years (excluding non-melanoma skin cancer that has received adequate treatment with no evidence of recurrence at least 3 months prior to the study intervention, or treated cervical carcinoma in situ with no evidence of recurrence at least 3 months prior to the study intervention).\n34. Breastfeeding women.\n35. The participant is currently enrolled in another ongoing clinical trial.\n36. Binge eating disorder; a history or presence of severe, progressive, or uncontrolled renal, genitourinary, hematologic, endocrine, cardiac, vascular, pulmonary, rheumatic, neurological, psychiatric disorders, or metabolic disturbances; or any other psychological or physical condition deemed by the investigator to render the participant unsuitable for participation in the clinical trial.\n37. The patient is in critical condition or has an expected lifespan of less than 5 years.","ALL","18 Years","70 Years",{"count":20,"type":21},20,"ESTIMATED","OBSERVATIONAL","experiment design: Single-center, single-arm, open-label trial\n\nInclusion Criteria:\n\n1. Ages 18-70.\n2. At least 6 months prior to enrollment, the patient must have been diagnosed with type 2 diabetes mellitus.\n3. The glycated hemoglobin level is 7.5%-10.5%.\n4. BMI 2 7-40 kg\u002Fm2.\n5. Patients who, within 12 weeks prior to screening, were treated with 2-3 oral hypoglycemic agents yet still had poorly controlled blood glucose levels, and could maintain the same medication regimen throughout the trial; or those whose blood glucose control was suboptimal despite lifestyle modifications.\n6. Stable body weight (defined as a weight change of \\\u003C5% within 5 weeks prior to screening)\n7. Donation of blood is prohibited during the trial participation period.\n8. The subject must sign an Informed Consent Form (ICF), demonstrating their understanding of the purpose and procedures required for this study and their willingness to participate.\n9. Be willing and able to comply with all requirements specified in the trial, including but not limited to completing the required assessments, adhering to the visit schedule, and complying with lifestyle restrictions.\n10. Fertile female subjects must have a negative urine pregnancy test result during screening and must use contraception throughout the study period.\n\nPrimary efficacy endpoint :HbA1c: The difference in HbA1c levels from the baseline period to 6 months post-treatment Observation period: 6 months postoperatively. Secondary efficacy endpoint HbA1c: The difference in HbA1c levels from the baseline period to after treatment Observation periods: 1 month, 3 months, and 12 months post-treatment. Average fasting blood glucose: The average fasting blood glucose level from the baseline period to after treatment Observation periods: 1 month, 3 months, 6 months, and 12 months post-treatment. Weight: Average weight from the baseline period to post-treatment Observation periods: 1 month, 3 months, 6 months, and 12 months post-treatment. Use of hypoglycemic agents: The incidence rate at which researchers determined the need for therapeutic intervention when glycated hemoglobin levels exceeded 8.5%.\n\nObservation periods: 1 month, 3 months, 6 months, and 12 months post-treatment. Safety Indicator 1. Adverse Events and Serious Adverse Events 2. Device defect 3. Intraoperative Instrument Performance Evaluation",[25],"Type 2 Diabetes Mellitus (T2DM)",[27,25],"pulsed electric field ablation system","RECRUITING","2026-06-25",{"date":31,"type":32},"2026-07-01","ACTUAL",{"date":34,"type":21},"2026-06-01",{"date":36,"type":21},"2028-12-31",{"name":38,"class":39},"Shanghai East Hospital","OTHER",1,{"id":42,"slug":43,"hasResults":12,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":12,"sex":47,"minAge":48,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":4},"100637680","a-multicenter-randomized-controlled-superiority-trial-comparing-robotic-assisted-versus-expert-cognitive-fusion-prostate-biopsy-in-obese-men-100637680","NCT07600216","A Multicenter, Randomized Controlled Superiority Trial Comparing Robotic-Assisted Versus Expert Cognitive Fusion Prostate Biopsy in Obese Men","Inclusion Criteria:\n\n* Age ≥ 40 years.\n* Serum PSA levels between 4 and 20 ng\u002Fml and\u002For abnormal digital rectal examination (DRE).\n* High Body Mass Index (BMI): defined as ≥ 28 kg\u002Fm ² for Asian cohorts and ≥ 30 kg\u002Fm ² for Non-Asian cohorts.\n* MRI-Positive: Presence of at least one suspicious lesion (PI-RADS score ≥ 3) on mpMRI.\n* Fitness for transperineal biopsy under local anaesthesia or conscious sedation.\n\nExclusion Criteria:\n\n* Prior treatment for prostate cancer.\n* History of major anorectal surgery preventing safe transperineal probe insertion.\n* Contraindications to MRI.\n* Negative screening MRI (PI-RADS 1-2).","MALE","40 Years",{"count":50,"type":21},570,"INTERVENTIONAL",[53],"NA","The trial aims to find out if using a robotic system to help perform prostate biopsies is better than having a highly experienced doctor perform the biopsy by hand in men with a high Body Mass Index (BMI).\n\nWhile MRI-guided prostate biopsies are highly effective, carrying them out in men with obesity can be physically challenging for doctors. Extra pelvic tissue increases the depth the biopsy needle must travel and makes it difficult to manually hold the ultrasound probe perfectly steady. This physical difficulty might cause doctors to miss some aggressive prostate cancers.\n\nThis study tests whether a robotic arm-which completely locks the biopsy needle on target and eliminates human hand tremors-can improve cancer detection. The study will enroll up to 570 men with high BMI who have suspicious areas on their prostate MRI. Participants will be randomly assigned to receive either a robotic-assisted biopsy or a standard manual biopsy performed by an expert urologist.\n\nTo ensure the results are completely unbiased, participants will not know which method is being used on them. They will be placed behind a surgical drape and wear noise-canceling headphones playing music during the procedure to block out the sounds of the robotic motors. The main goal is to see if the robotic method safely and significantly increases the detection rate of clinically significant prostate cancer in this specific group of patients.",[56],"Prostate Biopsy",[58,59],"prostate biopsy","targeted biopsy","NOT_YET_RECRUITING","2026-06-21",{"date":63,"type":32},"2026-06-24",{"date":65,"type":21},"2026-05-30",{"date":67,"type":21},"2028-05-30",{"name":38,"class":39},{"id":70,"slug":71,"hasResults":12,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":12,"sex":47,"minAge":76,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":51,"phases":79,"briefSummary":80,"conditions":81,"keywords":84,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":87,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":40},"100632633","mri-assisted-guidance-for-non-essential-tissue-sampling-100632633","NCT07516223","MRI-Assisted Guidance for Non-Essential Tissue Sampling","MRI-Assisted Guidance for Non-Essential Tissue Sampling (MAGNET): an Investigator-initiated, International, Multicentre, Prospective, Pairedcohort, Diagnostic Utility Study","Inclusion Criteria:\n\nAge ≥ 45 years. Serum PSA level ≥ 4.0 ng\u002Fml. High-risk MRI findings: Presence of at least one lesion with a PI-RADS score of 4 (Likely) or 5 (Highly Likely) according to v2.1 guidelines11.\n\nFitness for transperineal prostate biopsy under local or general anaesthesia. Competency to provide informed consent.\n\nExclusion Criteria:\n\nHistory of prior prostate biopsy (to ensure baseline risk homogeneity). Prior treatment for prostate cancer or use of 5-alpha reductase inhibitors (5-ARIs) within 6 months.\n\nCandidates who have explicitly opted for focal therapy prior to biopsy (where systematic mapping remains mandatory).\n\nContraindications to MRI (e.g., incompatible implants, severe renal impairment).\n\nActive urinary tract infection or acute prostatitis.","45 Years",{"count":78,"type":21},1235,[53],"The study aims to determine if a less painful and less invasive prostate biopsy approach is safe for certain men with a high risk of prostate cancer.\n\nCurrently, when a man has a suspicious MRI scan, standard medical guidelines recommend a \"combined biopsy.\" This means the urologist performs a Targeted Biopsy (taking 3-5 tissue samples directly from the suspicious area seen on the MRI) followed immediately by a Systematic Biopsy (taking 12 additional samples blindly from the rest of the prostate). While this combined approach maximizes cancer detection, the 12 extra needles from the systematic biopsy increase the risk of bleeding, pain, and urinary infection.\n\nResearchers believe that for men who already have a very high prostate-specific antigen (PSA) level and a highly suspicious MRI, the targeted biopsy alone might be enough to detect any dangerous cancer. In these high-risk men, the extra 12 systematic needles might offer little to no additional benefit (\"diminishing returns\").\n\nIn this study, 850 men will undergo the standard combined biopsy procedure. However, to test the researchers' theory with extreme precision, the tissue samples from the Targeted Biopsy and the Systematic Biopsy will be placed into completely separate, uniquely barcoded jars (the \"One Core, One Jar\" spatial mapping protocol). The pathologist will examine each tissue sample independently, without knowing which method was used to collect it.\n\nBy comparing the results within each patient, the study will determine exactly how many dangerous cancers were found exclusively by the systematic biopsy. If this number is clinically negligible (less than 5%) in men with high PSA levels, it will prove that the 12 extra needles are unnecessary for this specific group.\n\nThe ultimate goal of the trial is to safely \"de-escalate\" prostate cancer diagnostics-sparing high-risk men from the physical trauma, complications, and costs of unnecessary systematic sampling, while ensuring no dangerous cancers are missed.",[82,83],"PSA Progression","PSA",[58,59,85,86],"systematic biopsy","MRI",{"date":63,"type":32},{"date":89,"type":32},"2026-04-05",{"date":91,"type":21},"2028-05-05",{"name":38,"class":39},{"id":94,"slug":95,"hasResults":12,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":12,"sex":47,"minAge":100,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":51,"phases":103,"briefSummary":104,"conditions":105,"keywords":107,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":4},"100636931","high-frequency-irreversible-electroporation-vs-standard-of-care-for-benign-prostatic-hyperplasia-100636931","NCT07572097","High-Frequency Irreversible Electroporation vs Standard of Care for Benign Prostatic Hyperplasia","High-Frequency Irreversible Electroporation vs Standard of Care for Benign Prostatic Hyperplasia: Adaptive Platform Study","Inclusion Criteria:\n\nModerate-to-severe symptoms, defined as IPSS ≥13. Prostate volume (PV) between 30 and 150 ml, measured by multi-parametric MRI (mpMRI) or Transrectal Ultrasound (TRUS).\n\nMaximum urinary flow rate (Qmax) ≤15 ml\u002Fs. Note: To ensure validity, the voided volume during uroflowmetry must be ≥125 ml; tests with lower volumes must be repeated.\n\nCompetency to provide informed consent and comply with long-term follow-up.\n\nExclusion Criteria:\n\nSuspected or histologically confirmed prostate cancer. Patients with PSA \\>4 ng\u002Fml must undergo mpMRI; those with PI-RADS ≥3 lesions require a negative biopsy before enrolment.\n\nNeurogenic bladder, detrusor underactivity, or active urinary tract infection (UTI).\n\nPrevious prostate surgery, pelvic irradiation, urethral stricture, or bladder neck contracture.\n\nPresence of metallic implants incompatible with H-FIRE pulse delivery (e.g., non-compatible pacemakers).\n\nInability to safely discontinue anticoagulation if required by the assigned surgical protocol.","50 Years",{"count":102,"type":21},288,[53],"The study aims to find a better surgical treatment for men with an enlarged prostate (Benign Prostatic Hyperplasia, or BPH) that effectively relieves urinary symptoms without sacrificing sexual function.\n\nCurrently, standard surgeries like TURP or HoLEP are very effective at opening the blocked urinary channel. However, because they use heat or mechanical energy to remove prostate tissue, they often cause unwanted side effects, most notably the loss of normal ejaculation (retrograde ejaculation) and potential impacts on erectile function.\n\nThis study is testing a novel, minimally invasive technology called High-Frequency Irreversible Electroporation (H-FIRE). Instead of using heat to burn or cut the tissue, H-FIRE delivers ultra-short electrical pulses to destroy the blocking prostate tissue. This \"non-thermal\" (heat-free) approach is uniquely designed to spare the delicate nerves, blood vessels, and muscles surrounding the prostate, which are critical for preserving normal sexual function and bladder control.\n\nIn this clinical trial, 288 men aged 50 and older with moderate-to-severe BPH symptoms will be randomly assigned to receive either the investigational H-FIRE procedure or the Standard of Care surgery (TURP or HoLEP).\n\nThe main goal of the study is to prove that H-FIRE is just as effective as standard surgery in relieving lower urinary tract symptoms over 12 months. More importantly, the study will evaluate if H-FIRE is superior in helping patients achieve the \"BPH Trifecta\"-meaning the patient successfully achieves significant symptom relief, maintains perfect bladder control (uses zero pads), AND fully preserves normal ejaculation.\n\nBy utilizing this new tissue-sparing technology, the trial hopes to offer aging men a treatment option that restores their urinary health while fully protecting their overall quality of life.",[106],"BPH",[106,108,109,110],"h-fire","turp","holep","2026-04-29",{"date":113,"type":32},"2026-05-07",{"date":115,"type":21},"2026-05-05",{"date":117,"type":21},"2029-05-05",{"name":38,"class":39},{"id":120,"slug":121,"hasResults":12,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":126,"targetDuration":4,"studyType":51,"phases":128,"briefSummary":129,"conditions":130,"keywords":132,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":4},"100632859","pharmacological-intervention-to-prevent-noaf-after-tavr-100632859","NCT07519161","Pharmacological Intervention to Prevent NOAF After TAVR","Pharmacological Intervention for Atrial Arrhythmias to Prevent New-Onset Atrial Fibrillation After Transcatheter Aortic Valve Replacement: A Prospective, Multicenter, Randomized Controlled Trial","Inclusion Criteria:\n\n1. Undergoing TAVR for symptomatic severe aortic stenosis (defined as aortic valve area \\\u003C 1.0 cm², mean gradient ≥ 40 mmHg, or peak jet velocity ≥ 4.0 m\u002Fs).\n2. Sinus rhythm confirmed by a 24-hour Holter monitor within 72 hours pre-TAVR.\n3. Post-TAVR (within 24 hours) Holter monitoring or continuous telemetry reveals either:\n\n   * ≥1,000 premature atrial contractions (PACs) per 24 hours; OR\n   * Episodes of atrial tachycardia lasting 3 to 30 seconds.\n4. Provided written informed consent.\n\nExclusion Criteria:\n\n1. Known history of paroxysmal or persistent atrial fibrillation\u002Fflutter prior to TAVR.\n2. Presence of other significant arrhythmias pre-TAVR (e.g., \\>1,000 premature ventricular contractions\u002F24h, Mobitz Type I second-degree AV block or higher, sick sinus syndrome).\n3. Current use of antiarrhythmic drugs (including beta-blockers, amiodarone, propafenone) prior to randomization.\n4. Concurrent participation in another investigational device or drug study that could confound results.\n5. Contraindications to amiodarone or metoprolol (e.g., severe bradycardia, cardiogenic shock, thyroid dysfunction, severe liver disease, QT prolongation).\n6. Undergoing any other concurrent cardiac surgical procedure.",{"count":127,"type":21},198,[53],"The goal of this clinical trial is to learn if amiodarone or metoprolol works to prevent new-onset atrial fibrillation (AF) in patients who develop certain atrial arrhythmias after transcatheter aortic valve replacement (TAVR). It will also learn about the safety of these drugs. The main questions it aims to answer are:\n\n* Do amiodarone or metoprolol reduce the incidence of new-onset AF within 90 days after TAVR?\n* What medical problems do participants have when taking amiodarone or metoprolol?\n\nResearchers will compare amiodarone and metoprolol to observation (no antiarrhythmic drug) to see if either drug reduces the development of new-onset AF.\n\nParticipants who meet the post-TAVR arrhythmia criteria will:\n\n* Be randomly assigned to receive amiodarone, metoprolol, or observation\n* Take the assigned drug (if applicable) according to a specified dosing regimen\n* Be monitored continuously during hospitalization and undergo follow-up assessments at 30, 60, and 90 days, including ECGs, Holter monitors, and laboratory tests",[131],"Atrial Fibrillation",[133,134,135,136,137,138],"Transcatheter aortic valve replacement","New-onset atrial fibrillation","Atrial tachycardia","Metoprolol","Amiodarone","Randomized controlled trial","2026-04-10",{"date":141,"type":32},"2026-04-15",{"date":143,"type":21},"2026-04-07",{"date":145,"type":21},"2030-03-31",{"name":38,"class":39},{"id":148,"slug":149,"hasResults":12,"nctId":150,"briefTitle":151,"officialTitle":151,"acronym":4,"eligibilityCriteria":152,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":153,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":155,"conditions":156,"keywords":158,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":40},"100628565","high-risk-transcriptome-molecular-prediction-study-of-mash-associated-colorectal-polyps-100628565","NCT07463287","High-Risk Transcriptome Molecular Prediction Study of MASH-Associated Colorectal Polyps","Inclusion Criteria:\n\n1. Diagnosis of MAFLD conforms to the \"Guidelines for the Prevention and Treatment of Non-alcoholic Fatty Liver Disease\" (2018 Edition);\n2. Male or female patients aged 18-70 years;\n3. Signed informed consent form and explanation of the specific study protocol.\n\nExclusion Criteria:\n\n1. Chronic liver disease due to other etiologies (alcoholic, viral, autoimmune, drug-induced, etc.), decompensated cirrhosis, primary liver cancer;\n2. Underlying diseases of other vital organs (heart, kidney, lung, etc.) and bleeding disorders;\n3. Individuals lacking legal capacity or with poor insight.",{"count":154,"type":21},100,"The goal of this observational study is to learn about the molecular characteristics of colorectal polyps in patients with metabolic dysfunction-associated steatohepatitis (MASH) compared to individuals without fatty liver, and to identify potential transcriptomic biomarkers for high-risk polyps. The main questions it aims to answer are: What are the key gene expression differences in adenomatous polyps between MASH patients and non-fatty liver individuals? Can specific high-risk transcriptional molecules in plasma and polyp tissue serve as biomarkers for MASH-related colorectal polyps? Participants already scheduled for colonoscopic polypectomy as part of their routine care will provide a small portion of their polyp tissue, residual plasma from standard blood tests, and allow use of their stored pathological slides for research; they will also be followed up every six months.",[157],"MASH - Metabolic Dysfunction-Associated Steatohepatitis",[159,160],"colorectal polyps","MASH","2026-03-10",{"date":163,"type":32},"2026-03-11",{"date":165,"type":32},"2025-04-30",{"date":167,"type":21},"2027-04-30",{"name":38,"class":39},{"id":170,"slug":171,"hasResults":12,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":175,"eligibilityCriteria":176,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":177,"enrollmentInfo":178,"targetDuration":4,"studyType":51,"phases":180,"briefSummary":182,"conditions":183,"keywords":187,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":40},"100614412","phase-2-thrombolysis-in-early-acute-ischemic-stroke-trial-blood-pressure-management-100614412","NCT07279259","Thrombolysis in Early Acute Ischemic Stroke Trial-Blood Pressure Management","Thrombolysis in Early Acute Ischemic Stroke Trial-Blood Pressure Management, EAST-BP","EAST-BP","Inclusion Criteria:\n\n1. Age 18 to 80 years (inclusive);\n2. Patients with acute ischemic stroke;\n3. Planned to receive intravenous thrombolysis within 4.5 hours of onset;\n4. Elevated blood pressure: Before receiving intravenous thrombolysis treatment, blood pressure is elevated: systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 100 mmHg (defined as two consecutive measurements within 2 minutes);\n5. Informed consent signed (or signed by a proxy).\n\nExclusion Criteria:\n\n1. Intracranial hemorrhage is indicated on CT or MRI (including parenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, subdural or epidural hematoma).\n2. History of intracranial hemorrhage; severe head trauma or stroke within the last 3 months.\n3. Intracranial tumors, giant intracranial aneurysms.\n4. Intracranial or spinal surgery within the last 3 months; major surgery within the last 2 weeks; arterial puncture at a site not easily compressed for hemostasis within the last 7 days.\n5. Gastrointestinal or urinary system bleeding within the last 3 weeks.\n6. Aortic dissection.\n7. Acute bleeding tendency, including platelet count \\\u003C 100×10\\^9\u002FL or other bleeding tendencies.\n8. Received low-molecular-weight heparin orally within 24 hours; taking warfarin with INR \\> 1.7 or PT \\> 15 seconds; used a new oral anticoagulant within 48 hours.\n9. Blood glucose \\\u003C 2.8 mmol\u002FL or \\> 22.2 mmol\u002FL.\n10. Large area cerebral infarction indicated on head CT or MRI (infarction area \\> 1\u002F3 of the middle cerebral artery territory).\n11. Active visceral hemorrhage, known bleeding diathesis or significant bleeding disorders within the past 6 months\n12. Severe ischemic stroke (NIHSS score \\> 25)\n13. Epileptic seizures at the time of stroke onset\n14. Pregnant or lactating women\n15. Various terminal diseases with an expected survival of ≤ 3 months\n16. Any other physical conditions where the doctor deems participation in this study may be detrimental to the patient\n17. Currently participating in other drug or device clinical trials\n18. mRS score \\> 2 before onset of the disease.","80 Years",{"count":179,"type":21},340,[181],"PHASE2","This study is a Phase II, exploratory, prospective, multicenter, open-label, randomized controlled clinical trial with blinded endpoint assessment setting on the safety of an adjusted versus a conventional blood pressure management strategy during intravenous thrombolysis in AIS patients, with a key focus on the incidence of symptomatic intracranial hemorrhage (sICH).",[184,185,186],"Stroke","Acute Ischemic Stroke","Thrombolysis",[188,189,190],"acute ischemic stroke","blood pressure","thrombolysis","2026-01-18",{"date":193,"type":32},"2026-01-21",{"date":195,"type":21},"2026-01-15",{"date":197,"type":21},"2028-08-05",{"name":38,"class":39},{"id":200,"slug":201,"hasResults":12,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":205,"eligibilityCriteria":206,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":207,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":209,"conditions":210,"keywords":211,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":216,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":40},"100593210","biomarkers-based-early-diagnosis-of-stroke-subtype-cohortbio-east-100593210","NCT07003477","Biomarkers Based EArly Diagnosis of STroke Subtype Cohort（Bio-EAST）","Biomarkers Based EArly Diagnosis of STroke Subtype Cohort, Bio-EAST","Bio-EAST","Inclusion Criteria:\n\n1. Age ≥ 18 years old;\n2. Suspected stroke at emergency department arrival (FAST score ≥ 2 points, must include limb weakness);\n3. Time of stroke symptom onset\u002Flast known normal within 3 hours.\n\nExclusion Criteria:\n\n1. Coma - no response to tactile or verbal stimuli;\n2. Severe comorbidities (such as tumors, severe COPD, severe heart failure, requiring assistance with daily living \\[unable to walk independently\\]);\n3. History of epilepsy or onset with seizure;\n4. Recent history of head trauma (\\\u003C 7 days);\n5. Blood glucose \\\u003C 2.8 mmol\u002FL.",{"count":208,"type":21},527,"Intracerebral hemorrhage carries high rates of mortality and disability, imposes a significant societal burden. Based on findings from our previous multicenter randomized controlled clinical trial (INTERACT4), we revealed that initiating intensive blood pressure reduction therapy within 2 hours of onset in ambulances can markedly enhance the prognosis of patients with intracerebral hemorrhage. Nevertheless, the lack of rapid pre-hospital diagnostic technology hinders its clinical application and promotion. Given that glial fibrillary acidic protein (GFAP), as a biomarker, has been clinically validated for its high specificity in diagnosing intracerebral hemorrhage, this project aims to leverage an industry-academia-research collaborative development model in partnership with Shanghai Jinguan Technology Co., Ltd. By focusing on the urgent need for rapid diagnosis in stroke emergency care, this project will integrate clinical resources from hospitals with technological advantages in product development from the industry. Through resource sharing and complementary strengths, we aim to develop GFAP rapid detection technology with single-molecule sensitivity utilizing internationally advanced silicon photonics technology. Our objectives further include establishing a Chinese cohort to validate the reliability of GFAP in diagnosing intracerebral hemorrhage and conducting multicenter randomized controlled clinical trials to ascertain the efficacy and safety of GFAP-guided pre-hospital intensive blood pressure reduction for patients with intracerebral hemorrhage. This study also aimed to explore other biomarkers to be combined with GFAP in order to improve its sensitivity in detecting ICH.",[184],[212,213,214,215],"stroke","Intracerebral hemorrhage","GFAP (glial fibrillary acidic protein)","Pre-hospital diagnosis",{"date":193,"type":32},{"date":218,"type":32},"2025-06-12",{"date":220,"type":21},"2028-11-30",{"name":38,"class":39},{"id":223,"slug":224,"hasResults":12,"nctId":225,"briefTitle":226,"officialTitle":227,"acronym":228,"eligibilityCriteria":229,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":230,"targetDuration":4,"studyType":51,"phases":232,"briefSummary":234,"conditions":235,"keywords":236,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":241,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":246,"locationsCount":40},"100593133","phase-3-early-aggressive-strategy-for-treatment-of-lipid-lowering-in-acute-ischemic-stroke-delivered-with-endovascular-therapy-for-large-artery-occlusion-100593133","NCT07002476","Early Aggressive Strategy for Treatment of Lipid-Lowering in Acute Ischemic Stroke Delivered With Endovascular Therapy for Large Artery Occlusion","A Prospective, Multicenter, Open-Label, Randomized Controlled Study of Early Intensive Lipid-Lowering in Endovascular Treatment for Acute Ischemic Stroke","EAST-LDL","Inclusion Criteria:\n\n* Adults (age 18 years and older);\n* Imaging diagnosis of acute ischemic stroke with anterior circulation large vessel occlusion (including: internal carotid artery, middle cerebral artery M1 and M2, anterior cerebral artery A1 and A2);\n* Planned to undergo endovascular intervention within 24 hours of symptom onset (or last known well time) according to local guidelines;\n* Provision of informed consent by the patient or his\u002Fher legally authorized representative (or by an appropriate agent according to local requirements).\n\nExclusion Criteria:\n\n* ASPECTS score ≤5 on cranial CT imaging;\n* Pre-existing functional impairment, with mRS score \\>2;\n* Patients who are allergic to PCSK9 inhibitors;\n* Patients who have received PCSK9 monoclonal antibody within 1 month prior to enrollment or PCSK9 siRNA therapy within 6 months prior to enrollment;\n* Severe renal insufficiency, defined as estimated glomerular filtration rate (eGFR) \\\u003C 15 mL\u002Fmin\u002F1.73m2 at final screening;\n* Active liver disease or hepatic dysfunction, defined as aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \\> 3 times the upper limit of normal;\n* Severe, concomitant non-cardiovascular disease expected to reduce life expectancy to less than 3 months;\n* Pregnant or lactating women;\n* Patients who are participating in other clinical trials;\n* Other conditions deemed unsuitable for inclusion in the clinical study by the investigator.",{"count":231,"type":21},652,[233],"PHASE3","A prospective, multicenter, open-label, randomized controlled study to assess the effects of early intensive lipid-lowering initiated before endovascular treatment setting on (i) functional outcome in patients with acute ischemic stroke between preoperative intensive lipid-lowering therapy with PCSK9 inhibitor (PCSK9i) and guideline-recommended standard of care (SoC)(ii) safety in these patients.",[184],[188,237,238,239,240],"LDL-Cholersterol lowering","Endovascular Therapy","PCSK9","clinical trials",{"date":193,"type":32},{"date":243,"type":32},"2025-06-19",{"date":245,"type":21},"2029-01-01",{"name":38,"class":39},{"id":248,"slug":249,"hasResults":12,"nctId":250,"briefTitle":251,"officialTitle":252,"acronym":4,"eligibilityCriteria":253,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":254,"enrollmentInfo":255,"targetDuration":4,"studyType":51,"phases":257,"briefSummary":258,"conditions":259,"keywords":261,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":40},"100615300","effect-of-non-invasive-neuromodulation-on-the-quality-of-intestinal-cleansing-100615300","NCT07290816","Effect of Non-invasive Neuromodulation on the Quality of Intestinal Cleansing","Effect of Non-invasive Neuromodulation on the Quality of Bowel Cleansing: a Randomized, Controlled, Double-blind Clinical Study","Inclusion Criteria:\n\n* 18 to 78 years of age, male or female;\n* Intended to undergo diagnostic, screening, or surveillance colonoscopy;\n* Signed written informed consent.\n\nExclusion Criteria:\n\n* Severe cardiac, cerebral, pulmonary, or renal complications or a history of acute cardiac infarction within six months;\n* High risk factors for bowel preparation such as history of colon surgery, BMI ≥ 28, inflammatory bowel disease, constipation (less than 3 bowel movements in the last week, and with straining to defecate, with hard stools and small amount of stools) or bowel obstruction;\n* High suspicion of colorectal cancer by auxiliary examination or early warning signs and symptoms of colorectal cancer: blood in stool, black stool, unexplained anemia, significant weight loss, abdominal mass and positive rectal fingerprinting;\n* The presence of surgical incisions or scars in the area where the electrostimulation treatment tablets are pasted, or near the ST36 acupoints on both legs;\n* Are participating in other clinical observation trials or have participated in other clinical trials within 30 days.","78 Years",{"count":256,"type":21},270,[53],"To clarify whether non-invasive neuromodulation for assisted bowel preparation can improve the quality of bowel preparation, to explore the possible mechanisms by which TEA improves the quality of bowel preparation, and to assess its safety, as well as subjects' tolerance, compliance and satisfaction.",[260],"Intestinal Polyps",[262,263],"Bowel Preparation","Noninvasive electrical neuromodulation","2025-12-17",{"date":266,"type":32},"2025-12-18",{"date":268,"type":21},"2025-12-31",{"date":270,"type":21},"2028-03-21",{"name":38,"class":39},{"id":273,"slug":274,"hasResults":12,"nctId":275,"briefTitle":276,"officialTitle":277,"acronym":4,"eligibilityCriteria":278,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":279,"targetDuration":4,"studyType":51,"phases":281,"briefSummary":282,"conditions":283,"keywords":285,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":290,"startDateStruct":292,"completionDateStruct":294,"leadSponsor":295,"locationsCount":40},"100615583","effect-of-henagliflozin-on-myocardial-fibrosis-in-non-obstructive-hcm-a-randomized-double-blind-placebo-controlled-trial-using-68ga18f-fapi-petcmr-100615583","NCT07294495","Effect of Henagliflozin on Myocardial Fibrosis in Non-Obstructive HCM: A Randomized, Double-Blind, Placebo-Controlled Trial Using 68Ga\u002F18F-FAPI PET\u002FCMR","A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Effect of Henagliflozin on Myocardial Fibrosis Burden in Patients With Non-Obstructive Hypertrophic Cardiomyopathy Using 68Ga\u002F18F-FAPI PET\u002FCMR","Inclusion Criteria:\n\n1. Aged 18 years or older, regardless of gender.\n2. Meets the diagnostic criteria for non-obstructive hypertrophic cardiomyopathy (HCM):\n\n   * Confirmed diagnosis of HCM by cardiac magnetic resonance (CMR) or echocardiography (left ventricular wall thickness ≥15 mm, or ≥13 mm in the presence of a family history of HCM).\n   * Exclusion of patients in whom left ventricular hypertrophy is primarily attributable to hypertensive heart disease, as assessed by a cardiology specialist based on clinical and imaging evidence.\n   * Exclusion of other identifiable causes of secondary myocardial hypertrophy (e.g., valvular heart disease, storage cardiomyopathies).\n   * Left ventricular outflow tract (LVOT) gradient \\\u003C30 mmHg at rest or under provocation, as assessed by echocardiography or CMR.\n3. Willing to undergo FAPI PET\u002FCMR examination and complete imaging evaluations.\n4. Baseline FAPI PET\u002FCMR scan shows positive FAPI uptake: myocardial FAPI target-to-background ratio (TBR) ≥1.3, using the ascending aorta blood pool as the background reference.\n5. Capable of understanding and signing the informed consent form, and agrees to participate in the study, accept randomization, and comply with follow-up visits.\n6. New York Heart Association (NYHA) functional class I-III.\n\nExclusion Criteria:\n\n1. Significant left ventricular outflow tract obstruction (resting or provoked LVOT pressure gradient ≥30 mmHg).\n2. Coexistence of other identifiable causes of myocardial hypertrophy, including:\n\n   * Predominant or persistent hypertensive heart disease;\n   * Severe aortic stenosis or other significant valvular heart disease;\n   * Infiltrative or storage cardiomyopathies (e.g., Fabry disease, amyloidosis);\n   * Ischemic heart disease (e.g., severe coronary artery disease).\n3. Overt decompensated heart failure or NYHA functional class IV.\n4. Unstable, serious arrhythmias (e.g., sustained ventricular tachycardia, recent cardioversion for atrial fibrillation).\n5. Recent (within 3 months) cardiac surgery or interventional procedure.\n6. ALT or AST \\>3 times the upper limit of normal (ULN), OR total bilirubin (Tbil) \\>2 times ULN, OR ketonuria\u002Fketonemia, OR eGFR \\\u003C30 mL\u002Fmin\u002F1.73m², OR creatine kinase (CK) \\>3 times ULN.\n7. Concurrent other severe systemic disease with a life expectancy of less than 1 year.\n8. Pregnant or breastfeeding women.\n9. History of allergy to the study drug or any contraindication to its use.\n10. Any other condition deemed by the investigator to make the subject unsuitable for participation.",{"count":280,"type":21},150,[53],"his is a single-center, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the effect of Henagliflozin (an SGLT2 inhibitor) on myocardial fibrosis burden in patients with non-obstructive hypertrophic cardiomyopathy (nHCM). The study will use 68 68 Ga\u002F 18 18 F-FAPI PET\u002FCMR imaging to quantitatively assess changes in active fibroblast activity after 6 months of treatment. A total of 150 eligible adult patients with nHCM (FAPI-positive at baseline, NYHA class I-III) will be enrolled and randomized in a 1:1 ratio to either the Henagliflozin group (10 mg once daily) or the placebo group for a 6-month treatment period. The primary endpoint is the change in myocardial FAPI target-to-background ratio (ΔTBR) at 6 months. Secondary endpoints include changes in FAPI SUVmax, FAPI burden percentage (FAV%), cardiac structure and function parameters, 6-minute walk distance, NYHA classification, NT-proBNP levels, and quality-of-life scores. Exploratory analyses will assess clinical events over 12 months, such as heart failure hospitalization, atrial fibrillation, ventricular arrhythmias, and cardiovascular death. The study employs stratified block randomization based on baseline FAPI burden, central randomization and blinding via IWRS, independent core laboratory imaging evaluation, and an intention-to-treat analytical approach. It aims to provide early evidence for the anti-fibrotic effect of Henagliflozin in nHCM and to validate FAPI-PET\u002FCMR as an imaging biomarker for fibrosis activity.",[284],"HCM - Hypertrophic Cardiomyopathy",[286,287,288],"PET\u002FMR","FAPI","Hypertrophic Cardiomyopathy","2025-12-08",{"date":291,"type":32},"2025-12-19",{"date":293,"type":21},"2026-01-07",{"date":36,"type":21},{"name":38,"class":39},{"id":297,"slug":298,"hasResults":12,"nctId":299,"briefTitle":300,"officialTitle":300,"acronym":4,"eligibilityCriteria":301,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":302,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":304,"conditions":305,"keywords":307,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":309,"lastUpdatePostDateStruct":310,"startDateStruct":312,"completionDateStruct":314,"leadSponsor":315,"locationsCount":4},"100597173","the-diagnostic-efficacy-and-lesion-detection-advantages-of-18f-fdg-petcontrast-enhanced-mri-in-malignant-liver-lesions-100597173","NCT07055048","The Diagnostic Efficacy and Lesion Detection Advantages of 18F-FDG PET\u002FContrast-enhanced MRI in Malignant Liver Lesions","Inclusion Criteria:\n\n* Age ≥18 years;\n* Patients with suspected liver metastases or hepatic lesions,\n* Ability to undergo 18F-FDG PET\u002FMRI examination;\n* Willingness to comply with study protocols.\n\nExclusion Criteria:\n\n* Patients with a history of allergic reactions to MRI contrast agents;\n* Pregnant or lactating women;\n* Patients with severe comorbidities, including: Cardiac disease，Renal failure，or Hepatic failure (Child-Pugh C);\n* Patients unable to cooperate with PET\u002FMRI procedures.",{"count":303,"type":21},60,"Liver disease, a major global health burden, ranges from mild dysfunction to severe conditions like cirrhosis and hepatocellular carcinoma (HCC), the fifth most common cancer. Accurate diagnosis of liver lesions-distinguishing benign from malignant-is vital for treatment planning. Conventional imaging (ultrasound, CT, MRI) has limitations in sensitivity and detecting small metastases. PET\u002FCT combines metabolic and anatomical data but struggles with small lesions and cirrhotic livers.\n\n18F-FDG PET\u002FMRI with contrast-enhanced MRI may improve diagnostic accuracy, but its clinical benefits remain uncertain. Further research is needed to evaluate its performance, impact on patient outcomes, and cost-effectiveness in liver disease management.",[306],"Liver Cancer, Adult",[286,308],"liver cancer","2025-07-03",{"date":311,"type":32},"2025-07-08",{"date":313,"type":21},"2025-06-30",{"date":268,"type":21},{"name":38,"class":39},{"id":317,"slug":318,"hasResults":12,"nctId":319,"briefTitle":320,"officialTitle":320,"acronym":4,"eligibilityCriteria":321,"healthyVolunteers":322,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":323,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":325,"conditions":326,"keywords":328,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":309,"lastUpdatePostDateStruct":330,"startDateStruct":332,"completionDateStruct":334,"leadSponsor":335,"locationsCount":40},"100597788","clinical-research-on-68ga-fapi-petcmr-in-cardiovascular-diseases-100597788","NCT07063043","Clinical Research on 68Ga-FAPI PET\u002FCMR in Cardiovascular Diseases","Inclusion Criteria:\n\n* Participants must have a confirmed clinical diagnosis of cardiovascular disease by a cardiologist, based on genetic testing, family history, and comprehensive clinical evaluation including physical examination, echocardiography, and when indicated, cardiac MRI findings.\n* Age requirement: \\>18 years.\n* Patients should demonstrate stable cardiovascular status without significant changes in symptoms, treatment, or clinical findings for a specified pre-enrollment period.\n* Participants must be capable of providing informed consent and willing to adhere to all study requirements, including follow-up procedures.\n\nExclusion Criteria:\n\n* History of malignancy\n* Documented cardiovascular diseases, including coronary artery disease, myocardial infarction, or related conditions\n* Implanted metallic devices (e.g., pacemakers, aneurysm clips) or other MRI-incompatible medical prostheses\n* Claustrophobia\n* Pregnancy or lactation\n* Known hypersensitivity to gadolinium-based contrast agents\n* Renal impairment (eGFR \\\u003C30 mL\u002Fmin\u002F1.73m² by CKD-EPI equation)",true,{"count":324,"type":21},40,"FAP-targeted PET imaging using 68Ga-FAPI enables early detection of myocardial fibrosis. Combined PET\u002FCMR provides comprehensive cardiac assessment without extra radiation. This advanced imaging approach improves diagnosis and personalized treatment for better patient outcomes.",[327],"Cardiovascular Diseases (CVD)",[329,287,286],"Cardiovascular diseases",{"date":331,"type":32},"2025-07-14",{"date":333,"type":32},"2024-12-01",{"date":36,"type":21},{"name":38,"class":39},{"id":337,"slug":338,"hasResults":12,"nctId":339,"briefTitle":340,"officialTitle":341,"acronym":4,"eligibilityCriteria":342,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":343,"targetDuration":345,"studyType":22,"phases":4,"briefSummary":346,"conditions":347,"keywords":350,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":352,"lastUpdatePostDateStruct":353,"startDateStruct":355,"completionDateStruct":357,"leadSponsor":359,"locationsCount":4},"100571434","efficacy-of-68ga-pentixafor-petmr-in-detecting-non-hodgkin-lymphoma-and-multiple-myeloma-lesions-100571434","NCT06720207","Efficacy of 68Ga-Pentixafor PET\u002FMR in Detecting Non-Hodgkin Lymphoma and Multiple Myeloma Lesions","Exploratory Study on the Efficacy of 68Ga-Pentixafor PET\u002FMR in Detecting Lesions in Non-Hodgkin Lymphoma and Multiple Myeloma","Inclusion Criteria:\n\n1. Age of 18 years or older\n2. ECOG \\\u003C 2\n3. Newly diagnosed patients with NHL and MM who have been confirmed or are highly suspected based on pathological examination\n4. Completion of 18F-FDG PET\u002FCT or PET\u002FMR imaging within the past week in our department\n\nExclusion Criteria:\n\n1. Pregnant and breastfeeding women;\n2. Individuals with severe hepatic and renal failure;\n3. Patients with concurrent malignancies;\n4. Individuals unable to remain supine for a duration of 30 minutes to complete the examination;\n5. Patients with diagnosed claustrophobia;\n6. Patients containing metallic implants;\n7. Individuals deemed unsuitable for participation in clinical trials by researchers.",{"count":344,"type":21},30,"3 Years","In this study, the investigators intend to utilize 68Ga-Pentixafor Positron Emission Tomography（PET） imaging for patients diagnosed with non-Hodgkin lymphoma (NHL) and multiple myeloma (MM). The investigators will compare the imaging results with those obtained from 18F-FDG imaging, and a correlation analysis will be performed to assess progression-free survival among patients. This analysis aims to evaluate the diagnostic efficacy and the potential for early prediction of treatment efficacy associated with 68Ga-Pentixafor in these specific conditions.",[348,349],"Non Hodgkin's Lymphoma","Multiple Myeloma (MM)",[286,348,351],"multiple myeloma","2025-06-24",{"date":354,"type":32},"2025-06-27",{"date":356,"type":21},"2025-07-01",{"date":358,"type":21},"2027-07-31",{"name":38,"class":39},{"id":361,"slug":362,"hasResults":12,"nctId":363,"briefTitle":364,"officialTitle":365,"acronym":4,"eligibilityCriteria":366,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":367,"targetDuration":4,"studyType":51,"phases":369,"briefSummary":370,"conditions":371,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":373,"lastUpdatePostDateStruct":374,"startDateStruct":376,"completionDateStruct":378,"leadSponsor":380,"locationsCount":40},"100592500","effect-of-in-place-slow-jogging-on-metabolic-dysfunction-associated-steatotic-liver-disease-100592500","NCT06994234","Effect of In-Place Slow Jogging on Metabolic Dysfunction-Associated Steatotic Liver Disease","Effect of In-Place Slow Jogging on Metabolic Dysfunction-Associated Steatotic Liver Disease: A Prospective Randomized Controlled Trial","Inclusion Criteria:\n\n1. Meeting the diagnostic criteria for MASLD.\n2. Aged between 18 and 70 years (inclusive), regardless of gender.\n3. Patients voluntarily participate in this clinical study, have signed the informed consent form, and agree to comply with all study requirements, including follow-up visits, examinations, and treatments.\n\nExclusion Criteria:\n\n1. Exclusion of other conditions causing liver injury, including alcoholic hepatitis, active hepatitis B or C virus infection, drug-induced hepatitis, autoimmune hepatitis, primary sclerosing cholangitis, Wilson's disease, α1-antitrypsin deficiency, liver cancer (or family history of liver cancer), etc.\n2. History of medication use for more than 2 weeks within the past year that may induce hepatic steatosis or steatohepatitis (e.g., amiodarone, methotrexate, systemic glucocorticoids, tetracycline, tamoxifen, estrogen exceeding hormone replacement doses, anabolic steroids, valproic acid, or other known hepatotoxins).\n3. Use of hepatoprotective drugs (including but not limited to reduced glutathione, glucurolactone, glycyrrhizin preparations, nicotinamide, bifendate, liver-protecting tablets, silymarin, polyene phosphatidylcholine, S-adenosylmethionine, ursodeoxycholic acid, vitamin E, or other herbal medicines affecting liver function) within 4 weeks prior to enrollment.\n4. Presence of ascites, variceal bleeding, hepatic encephalopathy, spontaneous bacterial peritonitis, or history of liver transplantation at randomization or previously, or planned liver transplantation.\n5. Concurrent type 1 diabetes.\n6. Severe cardiovascular, cerebrovascular, renal, or hematopoietic system diseases, as well as mood disorders (e.g., anxiety, depression) or psychiatric illnesses.\n7. Patients with any type of malignancy or a history of malignancy.\n8. HIV-positive status.\n9. Pregnant or breastfeeding women, or subjects of childbearing potential unwilling or unable to use effective contraception from the screening period until 6 months after discontinuation of the investigational drug.\n10. Participation in other interventional clinical trials within 12 weeks prior to screening.\n11. Patients with unstable weight (i.e., weight loss or gain exceeding 4 kg in the past 3 months) or those with conditions preventing participation in the exercise program.\n12. Other conditions deemed by the investigator as unsuitable for participation in this study.",{"count":368,"type":21},82,[53],"Evaluating the Effectiveness, Safety, and Feasibility of Stationary Ultra-Slow Running in Treating MASLD Patients.",[372],"Metabolic Dysfunction-Associated Steatotic Liver Disease","2025-05-20",{"date":375,"type":32},"2025-05-29",{"date":377,"type":21},"2025-06-20",{"date":379,"type":21},"2028-06-20",{"name":38,"class":39},{"id":382,"slug":383,"hasResults":12,"nctId":384,"briefTitle":385,"officialTitle":386,"acronym":4,"eligibilityCriteria":387,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":177,"enrollmentInfo":388,"targetDuration":4,"studyType":51,"phases":390,"briefSummary":391,"conditions":392,"keywords":394,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":398,"lastUpdatePostDateStruct":399,"startDateStruct":401,"completionDateStruct":403,"leadSponsor":405,"locationsCount":4},"100592273","the-impact-of-transcutaneous-vagus-nerve-stimulation-on-cardiovascular-events-in-patients-with-acute-myocardial-infarction-100592273","NCT06991283","the Impact of Transcutaneous Vagus Nerve Stimulation on Cardiovascular Events in Patients With Acute Myocardial Infarction","The Impact of Transcutaneous Vagus Nerve Stimulation on Cardiovascular Events in Patients With Acute Myocardial Infarction","\\*\\*Inclusion Criteria\\*\\*\n\n1. Age between 18 and 80 years old (including 18 and 80 years old).\n2. Patients with acute myocardial infarction who have undergone revascularization of the culprit vessel within 24 hours of onset.\n3. Willing to participate in this study and have signed the informed consent form.\n\n\\*\\*Exclusion Criteria\\*\\*\n\n1. Hemodynamically unstable, with cardiogenic shock, requiring medication to maintain blood pressure and heart rate.\n2. Baseline systolic blood pressure \\\u003C90 mmHg or diastolic blood pressure \\\u003C40 mmHg.\n3. Average heart rate under monitoring \\\u003C50 beats per minute.\n4. Patients with II or III degree atrioventricular (AV) block or sick sinus syndrome who have not had a permanent pacemaker implanted.\n5. Baseline (before the use of antiarrhythmic drugs) QTc interval ≥500 ms, PR interval \\>280 ms.\n6. Patients who are participating in other clinical studies.\n7. Other reasons deemed by the investigator as unsuitable for participation in this study.",{"count":389,"type":21},278,[53],"The acute mortality rate of acute myocardial infarction (AMI) reduced significantly due to emergency reperfusion and subsequent treatment strategies. However, it remains a major cause of disability and death globally. Recent studies have shown that systemic inflammation is associated with infarct size and adverse clinical outcomes after myocardial infarction. Therefore, attenuating the inflammatory response may be a therapeutic target for acute coronary syndromes and improve clinical outcomes. Preclinical and clinical data indicate that vagus nerve stimulation (VNS) plays an important role in reducing the inflammatory burden and improving myocardial ischemia. However, more clinical evidence is needed to elucidate the role of VNS in patients with acute myocardial infarction and its impact on cardiovascular events. Therefore, this study aims to investigate the effect of vagal nerve modulation intervention through a prospective, randomized controlled clinical research method.",[393],"Acute Myocardial Infarction (AMI)",[395,396,397],"acute myocardial infarcation","inflammation","vagus nerve stimulation","2025-05-19",{"date":400,"type":32},"2025-05-27",{"date":402,"type":21},"2025-06-01",{"date":404,"type":21},"2028-10-01",{"name":38,"class":39},{"id":407,"slug":408,"hasResults":12,"nctId":409,"briefTitle":410,"officialTitle":411,"acronym":412,"eligibilityCriteria":413,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":414,"targetDuration":4,"studyType":51,"phases":416,"briefSummary":417,"conditions":418,"keywords":420,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":398,"lastUpdatePostDateStruct":426,"startDateStruct":428,"completionDateStruct":429,"leadSponsor":431,"locationsCount":432},"100575521","phase-3-early-initiated-ambulance-delivered-levetiracetam-and-headposition-in-hyper-acute-stroke-trial-100575521","NCT06773364","Early Initiated Ambulance-delivered Levetiracetam and Headposition in Hyper-acute Stroke Trial","An Investigator Initiated and Conducted, Prospective, Multicentre, Randomised Outcome-blinded Study of Pre-hospital Initiated Levetiracetam and Headposition in Patients With Presumed Acute Stroke","EAST","Inclusion Criteria:\n\n* Adults (age ≥18 years);\n* Acute condition that is presumed due to acute stroke, defined on the FAST (Face, Arm, Speech, Time) screen (score ≥2 with an arm deficit);\n* Time ≤2 hours from last seen well;\n* Able to provide brief consent (if a waver of consent not approved by ethics committee).\n\nExclusion Criteria:\n\n* coma (no response to painful stimulation);\n* severe co-morbid disease (e.g. cancer, chronic airflow disease, severe dementia, severe heart failure, pre-existing disability \\[needing help with everyday activities\\]);\n* history of epilepsy or seizure at onset;\n* recent head injury;\n* hypoglycaemia (glucose \\\u003C2.8mmol\u002FL);\n* clear indications or contraindications (allergies) for levetiracetam;\n* lactating women;\n* clear indications for a particular head position or situations where either head position cannot be maintained (such as severe vomiting and inability to lie down, severe obesity with fatigue and difficulty sitting up, etc.).",{"count":415,"type":21},2423,[233],"This is an investigator initiated and conducted, multicentre, ambulance-delivered, prospective, randomised, open-label, blinded outcome (PROBE) study. EAST aims to evaluate the effects of pre-hospital levetiracetam and different head positions initiated in ambulance settings on the functional outcome of participants assessed at 90 days.",[419],"Suspected Stroke",[421,422,423,424,425],"Ambulance","Acute stroke","Levetiracetam","Head position","intervention",{"date":427,"type":32},"2025-05-22",{"date":165,"type":32},{"date":430,"type":21},"2029-12-31",{"name":38,"class":39},2,{"id":434,"slug":435,"hasResults":12,"nctId":436,"briefTitle":437,"officialTitle":438,"acronym":4,"eligibilityCriteria":439,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":440,"enrollmentInfo":441,"targetDuration":4,"studyType":51,"phases":442,"briefSummary":444,"conditions":445,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":447,"lastUpdatePostDateStruct":448,"startDateStruct":450,"completionDateStruct":452,"leadSponsor":454,"locationsCount":40},"100581685","early-phase-1-hucmscs-exosomes-for-the-treatment-of-active-ulcerative-colitis-100581685","NCT06853522","hucMSCs Exosomes for the Treatment of Active Ulcerative Colitis","A Randomized, Single-blind Clinical Study of Human Umbilical Cord Mesenchymal Stem Cell Exosomes for the Treatment of Moderate-to-severe Active Ulcerative Colitis After Existing Therapy Failure","Inclusion Criteria:\n\n1. Subjects have had UC for at least 3 months (since symptom onset). The diagnosis should be confirmed by clinical and endoscopic evidence and confirmed by histopathological reports (note: if no previous reports are available, endoscopy and histopathology may be performed at the time of screening).\n2. Subjects had active UC, defined as four-component Mayo score of 6-12 (inclusive), endoscopy score ≥2, rectal bleeding score ≥1, and bowel frequency score ≥1.\n3. 18 to 75 years old, weight ≥40 kg\n4. Meet at least one of the following a\u002Fb\u002Fc criteria: a. inadequate or non-response to one or more of the following treatments: i) oral prednisone ≥40mg\u002F day (or equivalent) or budesonide ≥9mg\u002F day or equivalent or beclomethasone ≥5mg\u002F day for at least 2 weeks. ii) At least 8 weeks of immunomodulators (AZA≥2 mg\u002Fkg\u002F day or 6-MP≥1.0mg\u002Fkg\u002F day \\[or lower doses, but 6-thioguanine nucleotides with therapeutic concentrations recorded\\]). iii) Oral administration of aminosalicylate (e.g. Mesalazine, salazine sulfopyridine, oxalazine, balsalazine) in accordance with the dosage and duration of the applicable local instructions. iv) The frontier therapy for UC has completed at least the induction dosing regimen, At doses greater than or equal to the approved instructions: anti-TNF anti-integrins (e.g., Vederizumab), JAK inhibitors (e.g., Tofaciib, Upatinib, or filgotinib), anti-IL-23 or anti-IL-12\u002F23 drugs for the treatment of UC (e.g., ulinumab), S1PR modulators (e.g., ozamod) b. Corticosteroid dependence: failure to taper successfully to \\\u003C10mg\u002F day of prednisone or equivalent or \\\u003C6mg\u002F day of budesonide or \\\u003C5mg\u002F day of beclometasone within 3 months of starting treatment (i.e., disease onset), or relapse occurs within 3 months of stopping corticosteroids. c. Intolerance to 1 or 2 of the following treatments (e.g., inability to reach the therapeutic dose or duration of treatment due to dose-limiting adverse reactions) i) corticosteroids: Adverse reactions associated with dose-limiting therapy may include, but are not limited to, infections, hyperglycemia, osteoporosis, insomnia, or psychiatric disorders. ii) Immunomodulators: Adverse reactions associated with dose-restricted therapeutic administration may include, but are not limited to, infection, nausea\u002Fvomiting, fatigue, myelosuppression, or liver toxicity.\n5. Being treated with any of the following permitted drugs during the study period and meeting the drug stabilization requirements (if applicable): a. Oral corticosteroids must be stable for at least 2 weeks before randomization at an equivalent dose of ≤20 mg prednisone or ≤9mg budesonide or ≤5mg beclomethasone per day. b. A steady dose of oral aminosalicylate should be maintained for at least 2 weeks before randomization. c.AZA, 6-MP, or MTX(≤15 mg\u002F week) should be maintained at a stable dose for at least 4 weeks before randomization.\n6. Participate voluntarily and sign a written informed consent. -\n\nExclusion Criteria:\n\n1. Diagnosis of CD or undefined colitis (IBD- undefined) or other types of colitis or enteritis that may confuse assessment of effectiveness.\n2. The current diagnosis is explosive colitis and\u002For toxic megacolon.\n3. Had received fecal microbial transplantation within 4 weeks prior to randomization.\n4. Had been hospitalized for UC within 2 weeks prior to screening.\n5. There is clear evidence of past or current low or high grade colon dysplasia, including dysplasia detected during screening colonoscopy that has not been completely resectable.\n6. Have any active or severe infection that does not resolve after adequate treatment.\n7. Hepatitis B, hepatitis C virus infection, tuberculosis, HIV, uncontrollable diabetes, mental illness.\n8. Have undergone organ transplantation requiring sustained immunosuppressive therapy.\n9. A history of cancer within the past 5 years (except for completely treated non-melanoma skin cell carcinoma or carcinoma in situ of the cervix after complete surgical removal). Subjects who have had a diagnostic evaluation that suggests malignancy (e.g., chest or breast imaging) and who cannot reasonably rule out malignancy after additional clinical evaluation will be excluded from this study.\n10. A history of drug or alcohol abuse in the 6 months prior to screening (as reported by the subject).\n\n    \\-","75 Years",{"count":324,"type":21},[443],"EARLY_PHASE1","To evaluate the safety and efficacy of hUC-MSCs-Exos in the treatment of ulcerative colitis.",[446],"Ulcerative Colitis (UC)","2025-04-25",{"date":449,"type":32},"2025-04-27",{"date":451,"type":21},"2025-05-30",{"date":453,"type":21},"2028-04-04",{"name":38,"class":39},{"id":456,"slug":457,"hasResults":12,"nctId":458,"briefTitle":459,"officialTitle":460,"acronym":4,"eligibilityCriteria":461,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":462,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":464,"conditions":465,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":468,"lastUpdatePostDateStruct":469,"startDateStruct":471,"completionDateStruct":473,"leadSponsor":475,"locationsCount":40},"100588297","an-observational-study-of-inflammatory-bowel-disease-ibd-patients-with-non-alcoholic-fatty-liver-disease-nafld-100588297","NCT06939569","An Observational Study of Inflammatory Bowel Disease (IBD) Patients With Non-alcoholic Fatty Liver Disease (NAFLD)","A Bidirectional, Multicenter Cohort Study of Inflammatory Bowel Disease (IBD) Patients With Nonalcoholic Fatty Liver Disease (NAFLD)","Inclusion Criteria:\n\n1. Subjects aged over 18 years (including borderline values), of either sex.\n2. Subjects consistented with the Chinese consensus on the diagnosis and treatment of IBD;\n3. Subjects able to cooperate with follow-up, participate in this study and sign the informed consent.\n\nExclusion Criteria:\n\n1. Subjects with incomplete clinical data;\n2. Subjects can not to cooperate with follow-up, and refuse to sign the informed consent;\n3. Subjects can not to cooperate with the completion of relevant examinations; 4 Pregnant women;\n\n5.Subjects with severe heart, lung, kidney and other organ diseases or cancer, and expected survival time less than 6 months.",{"count":463,"type":21},337,"Inflammatory bowel diseases (IBD), including ulcerative colitis and Crohn's disease, are currently of unknown etiology and incurable. In recent years, the incidence of IBD has increased dramatically in China, and it will become a common disease of digestive system in China. Mesenteric adipose tissue hyperplasia indicates disease activity in IBD patients, and abnormal lipid metabolism plays an important role in the pathogenesis of IBD.\n\nIn addition to intestinal symptoms, nonalcoholic fatty liver disease (NAFLD), also known as metabolic dysfunction associated fatty liver disease (MASLD), has become the most common extraintinal manifestation in IBD patients. What are the similarities and differences between IBD patients with and without MASLD? Does the occurrence and severity of MASLD affect the clinical efficacy of IBD and increase the adverse outcome of IBD? There are no relevant studies to date. We have previously completed the construction of a cohort of 290 IBD patients using the IBD patient database and biobank of Dongfang Hospital, based on which we completed a cohort study on the effect of small intestinal bacterial overgrowth on IBD disease activity. Based on this cohort, multi-center cooperation was carried out to establish an IBD research cohort by collecting basic clinical information and biological samples such as peripheral blood and intestinal mucosa. The clinical characteristics of IBD patients with MASLD were analyzed. logistic regression, COX regression, Kaplan-Meier survival curve and other methods were used. To investigate the effect of MASLD on the clinical efficacy and prognosis of inflammatory bowel disease (IBD). This project will provide efficient, full and reliable research-grade data with Chinese characteristics for IBD clinical research, and improve the level of regional diagnosis and treatment.",[466,467],"Inflammatory Bowel Disease (IBD)","Metabolic Dysfunction Associated Fatty Liver Disease","2025-04-20",{"date":470,"type":32},"2025-04-23",{"date":472,"type":21},"2025-05-01",{"date":474,"type":21},"2027-12-01",{"name":38,"class":39},{"id":477,"slug":478,"hasResults":12,"nctId":479,"briefTitle":480,"officialTitle":481,"acronym":4,"eligibilityCriteria":482,"healthyVolunteers":12,"sex":483,"minAge":17,"maxAge":484,"enrollmentInfo":485,"targetDuration":4,"studyType":51,"phases":486,"briefSummary":488,"conditions":489,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":491,"lastUpdatePostDateStruct":492,"startDateStruct":494,"completionDateStruct":496,"leadSponsor":498,"locationsCount":4},"100586123","phase-1-combined-therapy-of-photoelectric-instruments-and-human-umbilical-cord-mesenchymal-stem-cells-for-pigmentary-disorders-100586123","NCT06911281","Combined Therapy of Photoelectric Instruments and Human Umbilical Cord Mesenchymal Stem Cells for Pigmentary Disorders","Clinical Study on the Combination Therapy of Photoelectric Instruments and Human Umbilical Cord Mesenchymal Stem Cells for Pigmentary Disorders","Inclusion Criteria:\n\n1. Subjects must voluntarily participate in this study and sign a written informed consent form.\n2. Subjects are female patients with melasma aged between 18 and 60 years. Their diagnosis should conform to the \"Chinese Expert Consensus on Diagnosis and Treatment of Melasma (2021 Edition)\" formulated by the Pigmentary Disorders Subgroup of the Dermatovenereology Committee of the China Association of Integrative Medicine. The skin lesions manifest as light brown or dark brown patches of varying depths and with indistinct borders on the cheeks, forehead, and jaw. Subjects must be excluded from having post-inflammatory hyperpigmentation, naevus of Ota, Riehl's melanosis, pigmented lichen planus, and other skin diseases. Additionally, their melasma should have been in a stable phase for 3 months or more.\n3. Subjects have never undergone stem cell therapy or laser treatment for melasma.\n\nExclusion Criteria:\n\n1. Subjects with a history of photosensitivity or allergies to biological medications.\n2. Subjects who are pregnant or lactating.\n3. Subjects who have a history of alcohol abuse, drug addiction, or substance abuse in the past 24 months.\n4. Subjects with concurrent severe systemic diseases, malignancies, or psychiatric disorders.\n5. Subjects with active infections, including bacterial, fungal, and viral infections.\n6. Subjects with keloid constitution.\n7. Subjects with a history of severe sun exposure within 4 weeks before enrollment.\n8. Subjects deemed unsuitable for enrollment by the investigator for various reasons or any other conditions that the investigator believes may compromise the safety or compliance of the subject or hinder the successful completion of the study.","FEMALE","60 Years",{"count":344,"type":21},[487],"PHASE1","Melasma is a common and refractory pigmentary skin disorder manifested as light to dark brown patches on the facial skin. It belongs to disfiguring dermatoses and significantly affects the physical and mental well-being of patients. Conventional treatments for melasma, including pharmacological and photoelectric therapies, have high recurrence rates and suboptimal clinical efficacy. Preliminary evaluations of the therapeutic effects of human umbilical cord mesenchymal stem cells (MSCs) in melasma mouse models have shown that MSCs can significantly improve skin pigmentation, reduce malondialdehyde (MDA) levels indicating anti-aging effects, ameliorate skin inflammatory cell infiltration, and promote skin repair in these models. This study is a single-center, randomized controlled clinical trial aiming to build on previous experimental findings by combining MSCs with photoelectric therapy for the treatment of melasma. Patients will be divided into three groups of 10 each: Stem Cell Treatment Group 1, Stem Cell Treatment Group 2, and a Control Group. Group 1 will receive intravenous infusion of MSCs followed by multi-point injection into the melasma area in combination with 755nm picosecond laser treatment. Group 2 will receive multi-point injection of MSCs into the melasma area in combination with 755nm picosecond laser treatment. The Control Group will only receive 755nm picosecond laser treatment. Efficacy will be initially assessed based on parameters such as the Melasma Area and Severity Index (MASI), VISIA skin analysis, and patient satisfaction. The study aims to evaluate the efficacy and safety of MSCs combined with photoelectric therapy for melasma and to investigate the underlying mechanisms.",[490],"Mesenchymal Stem Cells；Pigmentary Disorders","2025-03-28",{"date":493,"type":32},"2025-04-04",{"date":495,"type":21},"2025-06",{"date":497,"type":21},"2027-12-31",{"name":38,"class":39},{"id":500,"slug":501,"hasResults":12,"nctId":502,"briefTitle":503,"officialTitle":504,"acronym":505,"eligibilityCriteria":506,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":484,"enrollmentInfo":507,"targetDuration":4,"studyType":51,"phases":509,"briefSummary":510,"conditions":511,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":513,"lastUpdatePostDateStruct":514,"startDateStruct":516,"completionDateStruct":518,"leadSponsor":520,"locationsCount":40},"100574921","clinical-study-of-induced-pluripotent-stem-cells-derived-motor-neuron-precursor-cell-therapy-for-amyotrophic-lateral-sclerosis-als-100574921","NCT06765564","Clinical Study of Induced Pluripotent Stem Cells Derived Motor Neuron Precursor Cell Therapy for Amyotrophic Lateral Sclerosis (ALS)","Clinical Study of Human Induced Pluripotent Stem Cells Derived Motor Neuron Precursor(iPSC-MNP) Cells for the Treatment of Amyotrophic Lateral Sclerosis (ALS)","iPSC-MNP","Inclusion Criteria:\n\n1. Patients themselves or their legal guardians must consent to undergo this treatment protocol and sign the Informed Consent Form (ICF).\n2. Age between 18 and 60 years, inclusive, with no gender restrictions.\n3. Diagnosed with ALS according to the World Federation of Neurology criteria, and the initial diagnosis date is between 6 to 24 months before the screening date.\n4. Patients who have received standard treatment in the past with poor efficacy or disease progression.\n5. Forced Vital Capacity (FVC) should be ≥50%.\n6. During any night of the screening period, the total time with peripheral blood oxygen saturation \\\u003C90% should not exceed 2%.\n7. Patients should be deemed by the investigator to be in good nutritional status, with a Body Mass Index (BMI) ≥18.5.\n8. Male patients and their spouses, as well as women of childbearing age, should agree to implement effective contraceptive measures from the time of signing the ICF until one year after the start of treatment.\n9. Patients should be able to cooperate in the collection and preservation of medical history data and the visit process.\n\nExclusion Criteria:\n\n1. Patients with symptoms of neuromuscular weakness but cannot be conclusively determined to have ALS.\n2. Patients diagnosed with severe cognitive impairment, clinical dementia, or major psychiatric disorders, including but not limited to schizophrenia, bipolar disorder, or severe depression, according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V).\n3. Patients with any disease that impairs nerve or muscle function, such as peripheral neuropathy or metabolic myopathy.\n4. Patients with a history of malignant tumors or a previous diagnosis of malignancy.\n5. Within the two weeks preceding the screening period, patients who experienced acute active infections requiring treatment with antibiotics, antiviral drugs, or antifungal medications.\n6. ALS patients with concomitant respiratory failure.\n7. Patients who have previously undergone any allogeneic cell therapy or organ transplantation.\n8. Patients who have Participated in other clinical trials within the three months prior to screening.\n9. Patients with a history of tracheostomy or those using mechanical ventilatory support.\n10. Patients with a documented history of severe allergic reactions to general anesthesia drugs or previous severe allergic reactions for other reasons.\n11. Patients with intracranial organic diseases causing increased intracranial pressure.\n12. Patients with elevated liver function test results during the screening period, such as total bilirubin \\>1.5 times the upper limit of normal (ULN), or aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \\>3 times ULN.\n13. Patients who have abnormal kidney function test results during the screening period, such as serum creatinine \\>1.5 mg\u002FdL or an estimated creatinine clearance rate \\\u003C60 mL\u002Fmin calculated by the Cockcroft and Gault formula.\n14. Other clinically significant laboratory abnormalities during the screening period.\n15. Patients with hepatitis A, active hepatitis B (HBsAg positive and HBV DNA ≥500 IU\u002Fml, excluding drug- or other-caused hepatitis), active hepatitis C (anti-HCV antibody positive and HCV RNA positive), hepatitis E, human immunodeficiency virus (HIV) antibody positive, or syphilis treponemal antibody positive.\n16. Patients with impaired consciousness.\n17. Coagulation abnormalities (prothrombin time \\[PT\\] or international normalized ratio \\[INR\\] \\>1.5 times ULN; activated partial thromboplastin time \\[APTT\\] \\>1.5 times ULN) or those currently receiving anticoagulation therapy.\n18. Poorly controlled hypertension, with systolic blood pressure \\>160 mmHg and\u002For diastolic blood pressure \\>100 mmHg after treatment.\n19. Severe diabetes with late complications; patients with other diseases affecting limb mobility (e.g., limping, osteoarthritis, rheumatoid arthritis, gout, etc.).\n20. Patients who have undergone surgery or experienced trauma (including fractures) in the past month.\n21. Pregnant or breastfeeding women.\n22. Patients who, in the opinion of the investigator, have poorly controlled systemic diseases or other conditions that make them unsuitable for participation in this clinical study.",{"count":508,"type":21},3,[53],"Amyotrophic lateral sclerosis (ALS) is a severe neurodegenerative disease in the human motor system characterized by the selective involvement of spinal cord anterior horn cells, brainstem motor nuclei, and the corticospinal tract. It predominantly presents as concurrent damage to upper and lower motor neurons.\n\nInduced pluripotent stem cells (iPSCs) are a type of induced pluripotent stem cell derived from autologous or allogeneic cell sources. They can differentiate into various functional cell types, including specific motor neuron cells. iPSCs are used for stem cell replacement therapy. iPSCs hold significant clinical potential for ALS treatment. The iPSC database with human leukocyte antigen characteristics may represent a promising technology. This technology has the potential to obtain high-quality cell products and reduce the risk of graft rejection. Moreover, human iPSCs have demonstrated a certain degree of efficacy in the transplantation of neural stem\u002Fprogenitor cells derived from ALS rodent models.\n\nThe potential mechanisms of iPSC therapy for ALS include: the differentiated motor neuron precursor cells can replace damaged motor neurons, and restore motor conduction function; by secreting neurotrophic factors, they protect neurons; through immune regulation, they inhibit inflammatory reactions, and slow the progression of ALS.\n\nXellsmart Biomedical (Suzhou) Co., Ltd. is developing an injectable solution for ALS treatment using human iPSC-derived motor neuron precursor cells to address the pressing need for ALS therapy.",[512],"ALS","2025-01-03",{"date":515,"type":32},"2025-01-09",{"date":517,"type":32},"2024-03-13",{"date":519,"type":21},"2025-05-13",{"name":38,"class":39},{"id":522,"slug":523,"hasResults":12,"nctId":524,"briefTitle":525,"officialTitle":525,"acronym":4,"eligibilityCriteria":526,"healthyVolunteers":322,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":527,"targetDuration":528,"studyType":22,"phases":4,"briefSummary":529,"conditions":530,"keywords":532,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":535,"lastUpdatePostDateStruct":536,"startDateStruct":537,"completionDateStruct":539,"leadSponsor":540,"locationsCount":4},"100574242","the-application-of-68ga-pentixafor-alongside-68ga-fapi-04-petmr-for-assessing-primary-aldosteronism-100574242","NCT06756737","The Application of 68Ga-Pentixafor Alongside 68Ga-FAPI-04 PET\u002FMR for Assessing Primary Aldosteronism.","Inclusion Criteria:\n\nResearch Group Inclusion Criteria - (1) Patients must be over 18 years of age. (2) Patients diagnosed by an endocrinologist as highly suspected or confirmed cases of primary aldosteronism according to the guidelines of the Endocrine Society will be included.\n\n1. The criteria for high suspicion are as follows:\n\n   ① Persistent hypertension \\>160\u002F100 mmHg, especially resistant hypertension (blood pressure remains \\>140\u002F90 mmHg despite treatment with three or more antihypertensive medications) accompanied by hypokalemia (serum potassium concentration \\\u003C3.5 mmol\u002FL); or ② Drug-resistant hypokalemia with or without hypertension; or ③ Persistent hypertension with plasma aldosterone concentration (PAC) \\>15 ng\u002Fdl and a plasma aldosterone-renin ratio (ARR) ≥30 (ng\u002Fdl)\u002F(ng\u002Fml\u002Fh) (when plasma renin activity \\\u003C0.1 ng\u002Fml\u002Fh, it is calculated as 0.1 ng\u002Fml\u002Fh).\n2. The criteria for confirming primary aldosteronism are as follows:\n\nUnder the conditions of high suspicion, a positive result from the captopril challenge test (CCT) must be met. The principles, examination process, and methods for positive assessment of the CCT are as follows:\n\n* Principle: Captopril is an angiotensin-converting enzyme inhibitor that can suppress the renin-angiotensin-aldosterone system in normal individuals, thereby reducing aldosterone secretion. However, it has no significant inhibitory effect on patients with autonomous aldosterone secretion, such as those with primary aldosteronism.\n\n  * Examination method: Discontinue aldosterone antagonists and angiotensin-converting enzyme inhibitors for 1-2 weeks. On the day of the test, the patient should remain seated or supine for at least 4 hours, then orally administer 25 mg of captopril, and maintain the same position for 2 hours before drawing blood to measure PAC and PRA levels.\n\n    * Evaluation of test results: Calculate the change rate of PAC before and after the test, as well as the ARR value after the test. Based on published data, a reduction in PAC of \\\u003C30% compared to pre-test levels or an ARR value \\>46.2 after the CCT is considered a diagnostic threshold for a positive test result.\n\n      (3) Imaging studies indicate the presence of unilateral or bilateral adrenal nodules or nodular hyperplasia in the patient.\n\n      (4) Prior to enrollment, patients will undergo echocardiography, and the results will be recorded. If left ventricular hypertrophy is indicated, the patient will be included in the primary aldosteronism group with myocardial hypertrophy; otherwise, they will be included in the primary aldosteronism group without myocardial hypertrophy. Control Group Inclusion Criteria (1) The patient is over 18 years of age.\n\n      (2) The systolic blood pressure is greater than or equal to 140 mmHg or the diastolic blood pressure is greater than or equal to 90 mmHg.\n\n      (3) The patient's biochemical tests indicate normal adrenal hormone secretion. (4) There are no identifiable causes of secondary hypertension. (5) Imaging studies suggest the presence of unilateral or bilateral adrenal nodules or nodular hyperplasia in the patient.\n\n      (6) the patient undergoes a cardiac ultrasound before enrollment, and the results are recorded. If the ultrasound indicates left ventricular hypertrophy, the patient is included in the primary hypertension group with myocardial hypertrophy; otherwise, they are included in the primary hypertension group without myocardial hypertrophy.\n\nExclusion Criteria:\n\n(1) Children, pregnant and lactating women, etc; (2) Patients with poor autonomous behavioral ability (such as inability to lie flat), severe claustrophobia, and critically ill patients requiring life support who are unable to cooperate in completing the examination; (3) Patients with severe liver and kidney failure; (4) Patients with a history of myocardial infarction, cardiomyopathy, myocarditis, or congenital heart disease in the past; (5) Patients who can not successfully undergo CMR examination, such as arrhythmia or inability to hold their breath. (6) Patients with other conditions that are not suitable for this examination.",{"count":303,"type":21},"12 Months","The objective of this observational study is to utilize the advantages of 68Ga-Pentixafor subtyping diagnosis and the diagnostic ability of 68Ga-FAPI-04 for cardiovascular disease to identify primary aldosterone patients in need of adrenal surgery using non-invasive methods, while also assessing the degree of myocardial injury. Providing new, simple, and comprehensive diagnostic approaches for patients with primary aldosteronism, and improving the accuracy of clinical decision-making, can help develop personalized treatment plans in the early stages, thereby improving the long-term prognosis of primary aldosteronism patients.",[531],"Primary Aldosteronism",[533,534],"PET\u002FCMR","Primary aldosteronism","2024-12-26",{"date":513,"type":32},{"date":538,"type":21},"2025-01-01",{"date":497,"type":21},{"name":38,"class":39},{"id":542,"slug":543,"hasResults":12,"nctId":544,"briefTitle":545,"officialTitle":545,"acronym":4,"eligibilityCriteria":546,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":177,"enrollmentInfo":547,"targetDuration":528,"studyType":22,"phases":4,"briefSummary":548,"conditions":549,"keywords":551,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":552,"lastUpdatePostDateStruct":553,"startDateStruct":555,"completionDateStruct":556,"leadSponsor":558,"locationsCount":40},"100570870","a-clinical-study-of-evaluating-myocardial-viability-in-ischemic-heart-disease-with-integrated-18f-fdg-petmr-100570870","NCT06712862","A Clinical Study of Evaluating Myocardial Viability in Ischemic Heart Disease with Integrated 18F-FDG PET\u002FMR","Inclusion Criteria:\n\n1. Adults under the age of 80\n2. Coronary angiography shows coronary artery disease, with at least 2 coronary arteries having a degree of stenosis greater than 80%\n3. ft ventricular ejection fraction (LVEF)\\\u003C40%\n4. Acute myocardial infarction onset for at least 3 months\n5. Patients with old myocardial infarction with no acute coronary artery events in the past 3 months\n6. Patients of pre implementation of coronary artery bypass grafting (CABG) or combined treatment with human umbilical cord mesenchymal stem cells (iPSC)\n7. Agree to participate in this clinical trial and sign an informed consent form\n8. Good compliance\n\nExclusion Criteria:\n\n* 1.Patients with diabetes or other patients with poor blood glucose control (fasting blood glucose value on the test day is greater than 10mmol\u002FL) 2.Patients who allergy to MR contrast agent 3.Electronic implants such as pacemakers, nerve stimulators, insulin pumps, cochlear implants 4.Patients who have undergone aneurysm surgery and have intracranial aneurysm clips 5.Patients who have undergone heart surgery and have an artificial heart valve 6.Patients with metal foreign objects in the eyes 7.Patients with metal implants and prostheses, or metal foreign bodies in other parts of body 8.Severe liver and kidney dysfunction 9.Accompanied by arrhythmia such as atrial fibrillation, cerebrovascular disease, and severe pulmonary heart disease 10.Pregnant or plan to pregnant within three months or lactating women 11.Critically ill patients who require the use of life support systems 12.Patients with claustrophobia 13.Other situations which clinical trial personnel deem it inappropriate to participate in this trial",{"count":154,"type":21},"The main purpose is to evaluate the accuracy of myocardial imaging obtained through integrated 18F-FDG PET\u002FMR in detecting viable myocardium. The secondary objective is to evaluate whether myocardial imaging obtained through integrated 18F-FDG PET\u002FMR can replace 18F-FDG PET combined with 99mTc MIBI SPECT\u002FCT gated myocardial perfusion imaging.",[550],"Ischemic Heart Disease",[533,550],"2024-11-27",{"date":554,"type":32},"2024-12-02",{"date":268,"type":21},{"date":557,"type":21},"2026-12-31",{"name":38,"class":39},{"id":560,"slug":561,"hasResults":12,"nctId":562,"briefTitle":563,"officialTitle":563,"acronym":4,"eligibilityCriteria":564,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":565,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":566,"conditions":567,"keywords":569,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":572,"lastUpdatePostDateStruct":573,"startDateStruct":575,"completionDateStruct":576,"leadSponsor":578,"locationsCount":4},"100569924","the-diagnostic-efficacy-and-lesion-detection-advantages-of-18f-fdg-petct-and-enhanced-mri-in-hepatic-malignancies-100569924","NCT06700564","The Diagnostic Efficacy and Lesion Detection Advantages of 18F-FDG PET\u002FCT and Enhanced MRI in Hepatic Malignancies","Inclusion Criteria:\n\n1. Age ≥ 18 years old; Preliminary findings from other routine imaging examinations;\n2. Patients suspected of having liver metastasis or liver lesions, based on clinical symptoms and laboratory tests (such as alpha-fetoprotein levels);\n3. Preliminary findings from other routine imaging examinations;\n4. Able to perform 18F-FDG PET\u002FMR examination and agree to follow the research procedure.\n\nExclusion Criteria:\n\n1. Patients with a history of allergy to MR contrast agents;\n2. Pregnant or lactating women;\n3. Patients with severe heart disease, renal failure, liver failure, etc;\n4. Patients who are unable to cooperate in completing PET\u002FMR examinations.",{"count":303,"type":21},"Liver disease is a major challenge for global public health, covering a wide range from mild liver dysfunction to serious diseases such as cirrhosis and liver cancer. Globally, the high incidence rate and mortality of liver diseases have led to a huge socio-economic burden, especially in developing countries. Primary liver cancer, especially hepatocellular carcinoma (HCC), is the fifth most common cancer and the third leading cause of cancer death worldwide. In addition, the liver is a common site of metastasis for various cancers, and the occurrence of liver metastasis significantly affects the prognosis and treatment strategies of patients. In this context, accurately diagnosing the nature of liver lesions has become the key to improving patient treatment outcomes. Distinguishing between benign and malignant liver lesions is crucial for avoiding unnecessary invasive interventions and ensuring timely and appropriate treatment. Similarly, timely identification of liver metastases is crucial for the overall management and improvement of survival rates in cancer patients.\n\nTraditional imaging techniques such as ultrasound, computed tomography (CT), and magnetic resonance imaging (MRI) have been widely used for the detection and characterization of liver lesions, but they have limitations in diagnostic specificity and sensitivity, limited recognition of specific pathological features, and insufficient ability to detect small metastases. Positron emission tomography\u002Fcomputed tomography (PET\u002FCT), as a widely used fusion imaging technique, combines the metabolic information of PET with the anatomical information of CT, demonstrating unique value in the diagnosis and treatment evaluation of various tumors. However, PET\u002FCT has specific limitations in its application in liver diseases, especially in analyzing small liver lesions and distinguishing between benign and malignant tumors in the context of cirrhosis, which may be challenging. In addition, the radiation exposure caused by CT components is a significant issue that cannot be ignored in PET\u002FCT examinations.\n\nRelatively speaking, PET\u002FMR combined with 18F-fluorodeoxyglucose (18F-FDG)provides a new diagnostic possibility, especially when used in conjunction with abdominal-enhanced MR on the same machine, which is expected to further improve diagnostic accuracy. However, despite the theoretical superiority of this technology over traditional methods, the actual degree of improvement, scope of application, and impact on clinical decision-making are still unclear. Therefore, despite high expectations for this technology, it is necessary to conduct a comprehensive study to evaluate the specific benefits of 18F-FDG PET\u002FMR combined with abdominal-enhanced MR in the diagnosis of liver lesions, the particular degree of improvement in diagnostic accuracy, and its potential contribution to improving patient treatment outcomes. This not only helps to validate the practical application value of this technology in the diagnosis of liver lesions but also provides evidence for clinical doctors to optimize and personalize patient diagnosis and treatment plans. The results of this study will provide the scientific basis for future clinical practice, ensuring the effective and cost-effective application of this technology in the management of liver diseases.",[568],"Hepatoma",[568,570,571],"pet\u002Fmr","contrast-enhanced MR","2024-11-19",{"date":574,"type":32},"2024-11-22",{"date":333,"type":21},{"date":577,"type":21},"2027-11-30",{"name":38,"class":39},{"id":580,"slug":581,"hasResults":12,"nctId":582,"briefTitle":583,"officialTitle":584,"acronym":4,"eligibilityCriteria":585,"healthyVolunteers":322,"sex":16,"minAge":484,"maxAge":4,"enrollmentInfo":586,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":588,"conditions":589,"keywords":591,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":596,"lastUpdatePostDateStruct":597,"startDateStruct":599,"completionDateStruct":601,"leadSponsor":603,"locationsCount":40},"100567855","a-cohort-study-on-early-stages-of-heart-failure-100567855","NCT06673615","A Cohort Study on Early Stages of Heart Failure","A Community-based Cohort Study on Early Screening of Heart Failure in Elderly Population in Shanghai","Inclusion Criteria:\n\n1. Age ≥60 years\n2. Cooperate in participating in research and sign informed consent forms\n\nExclusion Criteria:\n\n1. End stage heart failure patients\n2. Refusal to participate in this study\n3. Patients who are not suitable to participate in this study by Researchers\\'s evaluation",{"count":587,"type":21},8000,"The main goal of this observational study is to learn about the epidemiological characteristics of heart failure among elder population in Beicai community in Shanghai and construct a community-based database and biobank. The main question it aims to answer is:\n\nWhat is the prevalence and prognosis of different stages of heart failure among elder population in community in Shanghai? And what are the influencing factors? What are the best screening strategies and hierarchical management strategies among different stages of heart failure patients in community? Participants are the elderly people aged 60 years or older in Beicai community in China. The follow-up will be programmed every 2 years.",[590],"Stages of Heart Failure",[592,593,594,595],"Heart failure","Early screening","Elderly population","Epidemiology","2024-11-02",{"date":598,"type":32},"2024-11-05",{"date":600,"type":32},"2024-04-15",{"date":602,"type":21},"2044-08-30",{"name":38,"class":39},""]